Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
Some mutation testing can be useful at CLL diagnosis
Publish date:
October 5, 2018
EXPERT ANALYSIS FROM MHM 2018
sworcester@mdedge.com
Pages
« first
1
2
Recommended Reading
Isavuconazole resolved invasive fungal disease in patients on ibrutinib
MDedge Hematology and Oncology
New chronic lymphocytic leukemia guidelines from the UK
MDedge Hematology and Oncology
Caution urged over real-world bleeding risk with ibrutinib
MDedge Hematology and Oncology
Combo treatment yields MRD-negative remissions in CLL
MDedge Hematology and Oncology
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
MDedge Hematology and Oncology
Venetoclax label now includes MRD data
MDedge Hematology and Oncology
FDA approves new hairy cell leukemia drug
MDedge Hematology and Oncology
FDA approves new drug for CLL/SLL and follicular lymphoma
MDedge Hematology and Oncology
Real-world clues for optimal sequencing of CLL novel agents
MDedge Hematology and Oncology
Novel options for treating hairy cell leukemia
MDedge Hematology and Oncology
CLL
Leukemia, Myelodysplasia, Transplantation
Indolent Lymphoma
Lymphoma & Plasma Cell Disorders
All Specialties
